Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone dose fractionation and red blood cell effects in transgender men
RBR-479v8tvPhase 3Recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of testosterone cypionate in Gender incongruence (GI) (2 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. Primary endpoint: Change in red blood cell parameters. Started Sep 2022; status: recruiting.
02
Drugs
testosterone cypionate
03
Conditions
Gender incongruence (GI)
Beyond the preview
Go deeper on RBR-479v8tv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-479v8tv.